Aerovate Therapeutics Stock Market Value
| AVTE Stock | USD 2.66 0.05 1.92% |
| Symbol | Aerovate |
Aerovate Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.99) | Return On Assets (0.49) | Return On Equity (0.82) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aerovate Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aerovate Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aerovate Therapeutics.
| 10/25/2024 |
| 11/24/2024 |
If you would invest 0.00 in Aerovate Therapeutics on October 25, 2024 and sell it all today you would earn a total of 0.00 from holding Aerovate Therapeutics or generate 0.0% return on investment in Aerovate Therapeutics over 30 days. Aerovate Therapeutics is related to or competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhanc... More
Aerovate Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aerovate Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aerovate Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.6 | |||
| Information Ratio | 0.1353 | |||
| Maximum Drawdown | 19.11 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 5.58 |
Aerovate Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aerovate Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aerovate Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aerovate Therapeutics historical prices to predict the future Aerovate Therapeutics' volatility.| Risk Adjusted Performance | 0.1393 | |||
| Jensen Alpha | 0.4909 | |||
| Total Risk Alpha | 0.0402 | |||
| Sortino Ratio | 0.1893 | |||
| Treynor Ratio | 0.6077 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aerovate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aerovate Therapeutics Backtested Returns
Aerovate Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Aerovate Therapeutics secures Sharpe Ratio (or Efficiency) of 0.15, which signifies that the company had a 0.15% return per unit of risk over the last 3 months. By analyzing Aerovate Therapeutics' technical indicators, you can evaluate if the expected return of 0.54% is justified by implied risk. Please makes use of Aerovate Therapeutics' Downside Deviation of 2.6, mean deviation of 2.55, and Risk Adjusted Performance of 0.1393 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Aerovate Therapeutics holds a performance score of 11. The firm shows a Beta (market volatility) of 1.01, which signifies a somewhat significant risk relative to the market. Aerovate Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Aerovate Therapeutics is expected to follow. Please check Aerovate Therapeutics' treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Aerovate Therapeutics' price patterns will revert.
Auto-correlation | 0.09 |
Virtually no predictability
Aerovate Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Aerovate Therapeutics time series from 25th of October 2024 to 9th of November 2024 and 9th of November 2024 to 24th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aerovate Therapeutics price movement. The serial correlation of 0.09 indicates that less than 9.0% of current Aerovate Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.09 | |
| Spearman Rank Test | 0.33 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Aerovate Therapeutics lagged returns against current returns
Autocorrelation, which is Aerovate Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Aerovate Therapeutics' stock expected returns. We can calculate the autocorrelation of Aerovate Therapeutics returns to help us make a trade decision. For example, suppose you find that Aerovate Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Aerovate Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Aerovate Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Aerovate Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Aerovate Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Aerovate Therapeutics Lagged Returns
When evaluating Aerovate Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Aerovate Therapeutics stock have on its future price. Aerovate Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Aerovate Therapeutics autocorrelation shows the relationship between Aerovate Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Aerovate Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:Check out Aerovate Therapeutics Correlation, Aerovate Therapeutics Volatility and Aerovate Therapeutics Alpha and Beta module to complement your research on Aerovate Therapeutics. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Aerovate Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.